<SEC-DOCUMENT>0001157523-13-004613.txt : 20131002
<SEC-HEADER>0001157523-13-004613.hdr.sgml : 20131002
<ACCEPTANCE-DATETIME>20131002151123
ACCESSION NUMBER:		0001157523-13-004613
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20130930
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20131002
DATE AS OF CHANGE:		20131002

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANIKA THERAPEUTICS INC
		CENTRAL INDEX KEY:			0000898437
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				043145961
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14027
		FILM NUMBER:		131129960

	BUSINESS ADDRESS:	
		STREET 1:		236 WEST CUMMINGS PARK
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801
		BUSINESS PHONE:		6179326616

	MAIL ADDRESS:	
		STREET 1:		236 WEST CUMMINGS PARK
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANIKA RESEARCH INC
		DATE OF NAME CHANGE:	19930309
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a50721411.htm
<DESCRIPTION>ANIKA THERAPEUTICS, INC. 8-K
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2013 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-size: 10pt; font-family: Times New Roman">
    <p>

    </p>
    <p style="text-align: center">
      <font style="font-size: 17pt; font-family: Times New Roman"><b>UNITED
      STATES</b></font><b><font style="font-size: 17pt; font-family: Times New Roman"><br style="font-size: 17pt; font-family: Times New Roman"></font><font style="font-size: 17pt; font-family: Times New Roman">SECURITIES
      AND EXCHANGE COMMISSION</font></b><font style="font-size: 10pt"><br style="font-size: 10pt"></font><font style="font-size: 12pt">WASHINGTON,
      D.C. 20549</font>
    </p>
    <hr style="width: 100%; text-align: center; color: #000000; height: 1.0 pt">


    <p style="text-align: center">
      <br>
      <font style="font-size: 17pt; font-family: Times New Roman"><b>FORM 8-K</b></font><br><br><br><font style="font-size: 10pt; font-family: Times New Roman"><b>CURRENT
      REPORT</b></font><b><font style="font-size: 10pt; font-family: Times New Roman"><br style="font-size: 10pt; font-family: Times New Roman"></font><font style="font-size: 10pt; font-family: Times New Roman">PURSUANT
      TO SECTION 13 OR 15(d) OF THE</font></b><br><font style="font-size: 10pt; font-family: Times New Roman"><b>SECURITIES
      EXCHANGE ACT OF 1934</b></font><br>
    </p>
    <hr style="width: 100%; text-align: center; color: #000000; height: 1.0 pt">


    <p style="text-align: center">

    </p>
    <p style="text-align: center">
      <font style="font-size: 10pt; font-family: Times New Roman">Date of
      Report (Date of earliest event reported): </font><font style="font-size: 10pt; font-family: Times New Roman"><b>September
      30, 2013</b></font><font style="font-size: 10pt; font-family: Times New Roman"><br style="font-size: 10pt; font-family: Times New Roman"></font><br>
    </p>
    <div style="text-align:center">
    <table style="font-size: 10pt; width: 100%; margin-bottom: 10.0px; font-family: Times New Roman; margin-left:auto;margin-right:auto" cellspacing="0">
      <tr>
        <td valign="top" style="padding-left: 0.0px; text-align: center">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <font style="font-size: 20pt; font-family: Times New Roman"><b>Anika
            Therapeutics, Inc.</b></font>
          </p>
        </td>
      </tr>
      <tr>
        <td valign="top" style="padding-left: 0.0px; text-align: center">
          <p style="margin-top: 0px; margin-bottom: 0px">
            (Exact Name of Registrant as Specified in Its Charter)
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <div style="text-align:center">
    <table style="font-size: 10pt; width: 100%; margin-bottom: 10.0px; font-family: Times New Roman; margin-left:auto;margin-right:auto" cellspacing="0">
      <tr>
        <td valign="bottom" style="width: 33%; padding-left: 0.0px; text-align: center">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>Massachusetts</b>
          </p>
        </td>
        <td valign="bottom" style="width: 34%; padding-left: 0.0px; white-space: nowrap; text-align: center; padding-right: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>000-21326</b>
          </p>
        </td>
        <td valign="bottom" style="width: 33%; padding-left: 0.0px; white-space: nowrap; text-align: center; padding-right: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>04-3145961</b>
          </p>
        </td>
      </tr>
      <tr>
        <td valign="top" style="width: 33%; padding-left: 0.0px; text-align: center">
          <p style="margin-top: 0px; margin-bottom: 0px">
            (State or Other Jurisdiction of<br>Incorporation)
          </p>
        </td>
        <td valign="top" style="width: 34%; padding-left: 0.0px; text-align: center">
          <p style="margin-top: 0px; margin-bottom: 0px">
            (Commission File<br>Number)
          </p>
        </td>
        <td valign="top" style="width: 33%; padding-left: 0.0px; text-align: center">
          <p style="margin-top: 0px; margin-bottom: 0px">
            (I.R.S. Employer Identification No.)
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <div style="text-align:center">
    <table style="font-size: 10pt; width: 100%; margin-bottom: 10.0px; font-family: Times New Roman; margin-left:auto;margin-right:auto" cellspacing="0">
      <tr>
        <td valign="top" style="width: 40%; padding-left: 0.0px; text-align: center">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>32 Wiggins Avenue, Bedford, Massachusetts</b>
          </p>
        </td>
        <td valign="bottom" style="width: 20%; padding-left: 0.0px; text-align: center">
          &#160;
        </td>
        <td valign="bottom" style="width: 40%; padding-left: 0.0px; white-space: nowrap; text-align: center; padding-right: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>01730</b>
          </p>
        </td>
      </tr>
      <tr>
        <td valign="top" style="width: 40%; padding-left: 0.0px; text-align: center">
          <p style="margin-top: 0px; margin-bottom: 0px">
            (Address of Principal Executive Offices)
          </p>
        </td>
        <td style="width: 20%">

        </td>
        <td valign="top" style="width: 40%; padding-left: 0.0px; text-align: center">
          (Zip Code)
        </td>
      </tr>
    </table>
    </div>
    <p>
      <br>

    </p>
    <p style="white-space: nowrap; text-align: center">
      Registrant&#8217;s Telephone Number, Including Area Code:<b>&#160;&#160;(781)
      457-9000</b><br>
    </p>
    <p style="text-align: center">
      <br>
      <b>No Change Since Last Report</b><br>&#160;(Former name or former address,
      if changed since last report.)<br>
    </p>
    <hr style="width: 100%; color: #000000; height: 1.0 pt; text-align: center">


    <p style="text-align: center">

    </p>
    <p>
      <font style="font-size: 10pt; font-family: Times New Roman">Check the
      appropriate box below if the Form 8-K filing is intended to
      simultaneously satisfy the filing obligations of the registrant under
      any of the following provisions:</font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      <font style="font-size: 10pt; font-family: Times New Roman">Written
      communications pursuant to Rule 425 under the Securities Act (17 CFR
      230.425)</font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      <font style="font-size: 10pt; font-family: Times New Roman">Soliciting
      material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)</font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      <font style="font-size: 10pt; font-family: Times New Roman">Pre-commencement
      communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
      240.14d-2(b))</font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      <font style="font-size: 10pt; font-family: Times New Roman">Pre-commencement
      communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
      240.13e-4(c))</font>
    </p>
    <div style="text-indent: 0pt; width: 100%; margin-bottom: 10pt; margin-right: 0pt; margin-left: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>

    </p>
    <p>
      <b>Item 1.01&#160; Entry into a Material Definitive Agreement.</b>
    </p>
    <p>
      N/A
    </p>
    <p>
      <b>Item 5.02&#160; Departure of Directors or Principal Officers; Election of
      Directors; Appointment of Principal Officers.</b>
    </p>
    <p>
      On September 27, 2013, Mr. Frank Luppino, Chief Operating Officer and
      the Registrant determined that Mr. Luppino would be leaving the company
      effective at the end of October.
    </p>
    <p>
      In its press release on October 2, 2013, the Registrant also announced
      the appointment of John W. Sheets, Jr., Ph.D., 60,<b> </b>as Chief
      Scientific Officer effective September 30, 2013.
    </p>
    <p>
      <b>Item 9.01:&#160; Financial Statements and Exhibits.</b>
    </p>
    <p>
      (d) Exhibits
    </p>
<div style="text-align:left">
    <table style="font-size: 10pt; width: 100%; margin-bottom: 10.0px; font-family: Times New Roman" cellspacing="0">
      <tr>
        <td valign="top" style="border-bottom: solid black 1.0pt; width: 10%; padding-left: 0.0px; text-align: left">
          <b>Exhibit No.</b>
        </td>
        <td valign="bottom" style="width: 4%; padding-bottom: 2.0px; padding-left: 0.0px; text-align: left">
          &#160;
        </td>
        <td valign="top" style="border-bottom: solid black 1.0pt; width: 86%; padding-left: 0.0px; text-align: center">
          <b>Description</b>
        </td>
      </tr>
      <tr>
        <td valign="top" style="width: 10%; padding-left: 0.0px; text-align: left">

        </td>
        <td valign="bottom" style="width: 4%; padding-left: 0.0px; text-align: left">

        </td>
        <td valign="top" style="width: 86%; padding-left: 0.0px; text-align: left">
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="width: 10%; padding-left: 0.0px; white-space: nowrap; text-align: left; padding-right: 0.0px">
          99.1
        </td>
        <td valign="bottom" style="width: 4%; padding-left: 0.0px; text-align: left">

        </td>
        <td valign="top" style="width: 86%; padding-left: 0.0px; text-align: left">
          Press Release issued by Anika Therapeutics, Inc. on October 2, 2013
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <div style="text-indent: 0pt; width: 100%; margin-bottom: 10pt; margin-right: 0pt; margin-left: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      <br>

    </p>
    <p style="text-align: center">
      <font style="font-size: 10pt; font-family: Times New Roman"><b>SIGNATURES</b></font><br><br>
    </p>
    <p>
      Pursuant to the requirements of the Securities Exchange Act of 1934, the
      registrant has duly caused this report to be signed on its behalf by the
      undersigned hereunto duly authorized.
    </p>
    <p>

    </p>
    <div style="text-align:center">
    <table style="font-size: 10pt; width: 100%; margin-bottom: 10.0px; font-family: Times New Roman; margin-left:auto;margin-right:auto" cellspacing="0">
      <tr>
        <td style="width: 50%">

        </td>
        <td colspan="3" valign="top" style="padding-left: 0.0px; text-align: left">
          <p style="margin-top: 0px; margin-bottom: 0px">
            ANIKA THERAPEUTICS, INC.
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 50%">

        </td>
        <td colspan="2" valign="top" style="padding-left: 0.0px; text-align: left">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td style="width: 12%">

        </td>
      </tr>
      <tr>
        <td valign="top" style="width: 50%; padding-bottom: 2.0px; padding-left: 0.0px; text-align: left">
          <p style="margin-top: 0px; margin-bottom: 0px">
            October 2, 2013
          </p>
        </td>
        <td valign="top" style="width: 4%; padding-bottom: 2.0px; padding-left: 0.0px; text-align: left">
          By:
        </td>
        <td valign="top" style="border-bottom: solid black 1.0pt; width: 34%; padding-left: 0.0px; text-align: left">
          <p style="margin-top: 0px; margin-bottom: 0px">
            /s/ Sylvia Cheung
          </p>
        </td>
        <td style="width: 12%">

        </td>
      </tr>
      <tr>
        <td style="width: 50%">

        </td>
        <td valign="top" style="width: 4%; padding-left: 0.0px; text-align: left">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td colspan="2" valign="top" style="padding-left: 0.0px; text-align: left">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Sylvia Cheung
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 50%">

        </td>
        <td valign="top" style="width: 4%; padding-left: 0.0px; text-align: left">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td colspan="2" valign="top" style="padding-left: 0.0px; text-align: left">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <i>Chief Financial Officer</i>
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <div style="text-indent: 0pt; width: 100%; margin-bottom: 10pt; margin-right: 0pt; margin-left: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>

    </p>
    <p style="text-align: center">
      <b>Exhibit Index</b>
    </p>
    <p>

    </p>
<div style="text-align:left">
    <table style="font-size: 10pt; width: 100%; margin-bottom: 10.0px; font-family: Times New Roman" cellspacing="0">
      <tr>
        <td valign="top" style="border-bottom: solid black 1.0pt; width: 10%; padding-left: 0.0px; text-align: left">
          <b>Exhibit No.</b>
        </td>
        <td valign="bottom" style="width: 4%; padding-bottom: 2.0px; padding-left: 0.0px; text-align: left">
          &#160;
        </td>
        <td valign="top" style="border-bottom: solid black 1.0pt; width: 86%; padding-left: 0.0px; text-align: center">
          <b>Description</b>
        </td>
      </tr>
      <tr>
        <td valign="top" style="width: 10%; padding-left: 0.0px; text-align: left">

        </td>
        <td valign="bottom" style="width: 4%; padding-left: 0.0px; text-align: left">

        </td>
        <td valign="top" style="width: 86%; padding-left: 0.0px; text-align: left">
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="width: 10%; padding-left: 0.0px; white-space: nowrap; text-align: left; padding-right: 0.0px">
          99.1
        </td>
        <td valign="bottom" style="width: 4%; padding-left: 0.0px; text-align: left">

        </td>
        <td valign="top" style="width: 86%; padding-left: 0.0px; text-align: left">
          Press Release issued by Anika Therapeutics, Inc. on October 2, 2013
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
  </body>
</html>
<!--<!DOCTYPE html
     PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN"
     "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">-->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a50721411ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2013 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-size: 8pt; font-family: Times New Roman">
    <p style="text-align: right">
      <b>Exhibit 99.1</b>
    </p>
    <p style="text-align: center">
      <font style="font-size: 12pt; font-family: Times New Roman"><b>Anika
      Therapeutics Appoints Industry-Recognized R&amp;D Executive John W. Sheets,
      Jr., Ph.D. as Chief Scientific Officer</b></font>
    </p>
    <p style="text-align: center">
      <i><font style="font-size: 12pt; font-family: Times New Roman"><b>Anika
      Also Announces Resignation of COO Frank Luppino</b></font></i>
    </p>
    <p>
      BEDFORD, Mass.--(BUSINESS WIRE)--October 2, 2013--Anika Therapeutics,
      Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing
      and repair, based on hyaluronic acid (&#8220;HA&#8221;) technology, today announced
      it has appointed John W. Sheets, Jr., Ph.D. as its new Chief Scientific
      Officer. Dr. Sheets joins Anika from Boston Scientific, where he was
      Senior Vice President, Corporate Research. At Boston Scientific, he was
      responsible for revitalizing product development by establishing new
      global processes, creating worldwide technology strategies, and
      establishing new product sourcing and development networks with a focus
      on emerging markets.
    </p>
    <p>
      Dr. Sheets replaces Jing-wen Kuo, Ph.D. who is leaving to pursue other
      opportunities at the end of October. In addition to driving Anika&#8217;s
      research and development efforts, Dr. Sheets is leading the company&#8217;s
      regulatory, clinical affairs and engineering functions. These previously
      were overseen by COO Frank Luppino, who is leaving Anika at the end of
      October to pursue other interests. Mr. Luppino&#8217;s remaining
      responsibilities are being smoothly transitioned to existing senior
      executives, with operations management reporting directly at the CEO
      level.
    </p>
    <p>
      &#8220;John&#8217;s appointment as Chief Scientific Officer to oversee our
      technology and pipeline development provides us with significantly
      stronger leadership in those critical areas,&#8221; said Charles H. Sherwood,
      Ph.D., Anika&#8217;s President and CEO. &#8220;His R&amp;D expertise, multi-national
      partnership experience, and business acumen will be valuable assets as
      we advance Anika&#8217;s strategic initiatives and prepare the company for the
      next level of growth. As we welcome John, we also would like to thank
      Frank and Jing-wen for their many contributions to Anika&#8217;s past success.&#8221;
    </p>
    <p>
      Prior to his work at Boston Scientific, Dr. Sheets was Corporate Vice
      President of R&amp;D and Chief Technology Officer for Bausch and Lomb. He
      also served as President of Hoya Surgical Optics and worked for Ethicon
      (Johnson &amp; Johnson), Alcon Laboratories and Iolab Corporation (Johnson &amp;
      Johnson) in California. Dr. Sheets holds a B.S., a M.S., and a Ph.D. in
      Materials Science and Engineering from the University of Florida,
      Gainesville.
    </p>
    <p>
      <b>About Anika Therapeutics, Inc.</b>
    </p>
    <p>
      Headquartered in Bedford, Mass., Anika Therapeutics, Inc. develops,
      manufactures and commercializes therapeutic products for tissue
      protection, healing, and repair. These products are based on hyaluronic
      acid (HA), a naturally occurring, biocompatible polymer found throughout
      the body. Anika&#8217;s products range from orthopedic/joint health solutions
      led by Orthovisc<sup>&#174;</sup>, a treatment for osteoarthritis of the
      knee; to surgical aids in the anti-adhesion and ophthalmic fields. The
      company also offers aesthetic dermal fillers for the correction of
      facial wrinkles. Anika&#8217;s Italian subsidiary, Anika Therapeutics, S.r.l.,
      provides complementary HA products in orthopedic/joint health and
      anti-adhesion, as well as therapeutics in areas such as advanced wound
      treatment and ear, nose and throat care. Its regenerative technology
      advances Anika&#8217;s vision to offer therapeutic products that go beyond
      pain relief to protect and restore damaged tissues.
    </p>
    <div style="text-indent: 0pt; width: 100%; margin-bottom: 10pt; margin-right: 0pt; margin-left: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      <i>The statements made in this press release which are not statements of
      historical fact are forward-looking statements within the meaning of
      Section 27A of the Securities Act of 1933, as amended, and Section 21E
      of the Securities Exchange Act of 1934, as amended. These statements
      include, but are not limited to, those relating to the appointment of
      John Sheets, Jr., Ph.D. as Anika&#8217;s Chief Scientific Officer; the
      departure of Jing-wen Kuo, Ph.D. as the company&#8217;s Chief Scientific
      Officer; the departure of Frank Luppino as the company&#8217;s Chief Operating
      Officer; the nature and successful transition of Mr. Luppino&#8217;s
      responsibilities to existing senior executives; and the impact of
      management changes on its development initiatives and preparation of the
      company for the next level of growth.</i> <i>The company's actual
      results could differ materially from any anticipated future results,
      performance or achievements described in the forward-looking statements
      as a result of a number of factors including (i) the company's ability
      to successfully commence and/or complete clinical trials of its products
      on a timely basis or at all, obtain pre-clinical or clinical data to
      support a pre-market approval application or 510(k) application, or
      timely file and receive FDA or other regulatory approvals or clearances
      of its products, or that such approvals will not be obtained in a timely
      manner or without the need for additional clinical trials, other testing
      or regulatory submissions, as applicable; (ii) the company's research
      and product development efforts and their relative success, including
      whether the company has any meaningful sales of any new products
      resulting from such efforts; (iii) the cost effectiveness and efficiency
      of the company&#8217;s clinical studies, manufacturing operations and
      production planning; (iv) the strength of the economies in which the
      company operates or will be operating, as well as the political
      stability of any of those geographic areas; (v) future determinations by
      the company to allocate resources to products and in directions not
      presently contemplated; (vi) the company&#8217;s ability to launch Monovisc in
      the U.S., if at all; (vii) the company&#8217;s ability to provide an adequate
      and timely supply of its ophthalmic, Orthovisc and other products to its
      customers; (viii) the company&#8217;s ability to successfully manage and
      turnaround Anika S.r.l.&#8217;s business; and (ix) the company&#8217;s ability to
      achieve its stated growth targets.</i> <i>Certain other factors that
      might cause the company's actual results to differ materially from those
      in the forward-looking statements include those set forth under the
      headings &quot;Business,&quot; &quot;Risk Factors&quot; and &quot;Management's Discussion and
      Analysis of Financial Condition and Results of Operations&quot; in the
      company's Annual Report on Form 10-K for the year ended December 31,
      2012, as well as those described in the company's other press releases
      and SEC filings.</i>
    </p>
    <p style="text-align: center">

    </p>
    <p>
      CONTACT:<br>Anika Therapeutics, Inc.<br>Charles H. Sherwood, Ph.D.,
      President and CEO<br>Sylvia Cheung, CFO<br>781-457-9000
    </p>
    <p style="white-space: nowrap">

    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
